Pantoprazol Stada (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Stada, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Pantoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Stada is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcer disease: accelerates the healing of ulcer lesions. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder. - Prevention of NSA‑induced gastroduodenal ulcers: reduces the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Pantoprazol Stada is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation. - Dry mouth.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angio‑edema). - Clostridioides difficile‑associated colitis. - Acute interstitial nephritis. - Low magnesium levels (hypomagnesemia) with prolonged use. - Fractures of the hip, wrist or spine with long‑term therapy. - Liver enzyme elevations indicating possible hepatic injury.

Before initiating therapy, consider the following precautions: - Renal impairment: adjust dose in severe kidney disease. - Hepatic impairment: use with caution in moderate to severe liver dysfunction. - Elderly patients: monitor for dehydration and electrolyte disturbances. - Concomitant use of drugs that increase gastric pH: assess need for dose adjustment. - Long‑term therapy: evaluate bone health and magnesium status periodically. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: slight increase in serum concentration; observe for toxicity signs.